|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Angionetics Inc.
| | | Phone: | (858) 436-1000 | Year Established: | 2015 | Main Contact: | Christopher J. Reinhard, CEO | | Company Description | Angionetics is a biotechnology company, recently formed by Taxus Cardium, that has been designed to affect an asset "value unlock" of its undervalued technology platforms. As Angionetics advances forward with its plan to operate as a company independent of Taxus Cardium, it will focus on the clinical and commercial development of angiogenic, gene-based bio-therapeutics for the treatment of up to an estimated 1.2 million patients in the U.S. who have late-stage coronary artery disease and refractory angina, as well as other medical conditions due to myocardial ischemia. | |
|
|
|
|
|